Background: A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer.
introduction
Ovarian cancer is the sixth most common cancer overall in women in the United States and Europe, accounting for an estimated 230 555 new cases and 141 452 deaths worldwide in 2007 [1] . Most patients with epithelial ovarian cancer present with advanced-stage disease [FIGO (International Federation of Gynecology and Obstetrics) stage III or IV] [2] . Although the majority of patients enter remission after surgery and first-line chemotherapy, the recurrence rate is 80% [3] [4] [5] .
Patients with recurrent ovarian cancer are typically divided into three groups with different prognoses. Patients who relapse after a treatment-free interval of >6 months from completion of therapy are considered platinum sensitive; those whose disease relapses after a treatment-free interval of <6 months are considered platinum resistant, while those with progression on primary therapy are considered to have refractory disease [6] . While patients with platinum-sensitive disease have a good chance of secondary response when re-challenged with platinum chemotherapy [7] , the treatment options for patients with platinum-resistant disease are limited, with response rates that do not exceed 14% in randomised trials [6, 8, 9] .
In view of the dismal prognosis, new treatment approaches are therefore urgently required to improve outcome in platinum-resistant ovarian cancer. Epithelial ovarian cancer has been shown to be susceptible to antivascular therapy and preliminary data show efficacy of antiangiogenic therapies in the treatment of this disease [10] .
Tumour vascular disrupting agents (VDAs) target the existing vasculature to cause rapid vascular shutdown in the tumour, leading to cell death [11] . Combretastatin A4 phosphate (CA4P; fosbretabulin) [cis-1-(3,4, 5,-trimethoxyphenyl)-2-(4#-methoxyphenyl) ethene-3#-Ophosphate disodium salt] is a more water-soluble prodrug of the tubulin-binding VDA combretastatin A4 (CA4), derived originally from the bark of the African bush willow [12] . CA4P was generally well tolerated in three phase I trials in which 96 patients received CA4P as monotherapy, with neuropathy and tumour pain as main dose-limiting toxic effects [13] [14] [15] first trial combining CA4P with carboplatin resulted in doselimiting thrombocytopenia due to pharmacological interaction of the two substances when carboplatin was given before CA4P, probably because the CA4P temporarily reduced renal blood flow and carboplatin excretion [16] . A subsequent phase Ib dose-escalation trial of CA4P given a minimum of 18 h before carboplatin, paclitaxel, or both showed that the combination was well tolerated and haematologic toxicity was not higher than expected from paclitaxel-carboplatin combination treatment alone [17] . In the phase Ib trial, responses were seen in three patients with oesophageal cancer, small-cell lung cancer, and melanoma. However, responses according to RECIST and/or Gynecologic Cancer InterGroup (GCIG) CA 125 criteria were seen in 7 of 18 patients with ovarian, primary peritoneal, or fallopian tube cancer [17] . This single-arm phase II trial was conducted to confirm the safety and to evaluate the activity of combining CA4P with carboplatin and paclitaxel based on the doses evaluated in the phase Ib part of the trial [CA4P 63 mg/m 2 ; carboplatin AUC (area under the concentration curve) 5, based on glomerular filtration rate (GFR) measured by EDTA clearance; and paclitaxel 175 mg/m 2 ] in patients with platinum-resistant ovarian cancer [17] .
patients and methods

patient population
Women aged ‡18 years with histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube cancer whose disease had relapsed <6 months following treatment with a platinum-containing regimen in the adjuvant or metastatic setting were eligible for the study. An amendment was introduced after the inclusion of the first three patients stating that patients not only had to progress but also had to start trial treatment within 6 months after platinum chemotherapy. Patients had to have radiologically measurable disease and/or evaluable by CA 125. Two pretreatment samples greater than or equal to twice the upper limit of normal were required to be evaluable for response by CA 125. It was the policy of all participating centres to only enter patients because of radiological and/or symptomatic progression, not just based on raising CA 125.
Patients had to have an Eastern Cooperative Oncology Group performance status (PS) of two or less and adequate bone marrow (neutrophil count ‡1500 cells/mm 3 ; platelet count ‡100 000 cells/mm 3 ), hepatic (total bilirubin <1.5 mg/dl; alanine aminotransferase and aspartate aminotransferase <2.5· upper limit of normal), and renal function (GFR measured by EDTA clearance >50 ml/min). Study-specific criteria for exclusion were grade ‡2 neuropathy, major surgery within 4 weeks, prior radical radiotherapy or evidence of vascular damage from radiotherapy, history of peripheral vascular or cardiac disease or arrhythmias, QTc >450 ms, and uncontrolled hypertension (defined as blood pressure consistently greater than 150/100 mmHg irrespective of medication). Patients were recruited from five centres in the UK. The study was conducted according to the Declaration of Helsinki. The study was approved by the ethical review boards of the participating hospitals, and all enrolled patients provided written informed consent.
study design
This was a multicentre single-arm study in which patients received CA4P 63 mg/m 2 18-20 h before paclitaxel 175 mg/m 2 and carboplatin AUC 5.
Treatment was repeated every 3 weeks for up to six cycles [17] , or until patient withdrawal. On day 1 of each treatment cycle, patients received CA4P as a 10-min i.v. infusion. Routine CA4P premedication was not mandated but if toxicity occurred with the first course, premedication with dexamethasone and metoclopramide was suggested for future courses. On day 2, paclitaxel was given as a 3-h i.v. infusion, followed by a 1-h infusion of carboplatin. GFR was measured by EDTA clearance. The dose of carboplatin corresponding to a target AUC of 5 was calculated using a modified Calvert formula: carboplatin [dose per cycle in mg] = 5 · (GFR + 25).
treatment assessment
The primary end point of the study was response, based on RECIST [18] and or according to CA 125 response criteria agreed by the GCIG [19] . Tumour evaluations occurred at screening and then every two cycles.
Laboratory assessments were carried out weekly. Electrocardiographic assessments were conducted throughout the study. On day 1 of each cycle, three predose electrocardiograms (ECGs) were obtained, and single ECGs at every hour for 6 h after CA4P infusion. Blood pressure was monitored predose and at every hour for 6 h after CA4P infusion. If systolic blood pressure was >180 mmHg on two readings following CA4P, glyceryl trinitrate (GTN) 0.3 mg was given sublingually.
statistical analysis
Taking the historical response to chemotherapy in platinum-resistant patients to be 10%, Simon's tables were used to determine the sample size of total 43 patients required [20] . As an interim requirement, more than two responses (RECIST and/or GCIG) were required in the first 18 patients to ensure a response rate of at least 10% (using 80% power and a = 0.05, with the probability of early termination at 0.0395). If more than seven responses were seen in 43 patients (16%), then we would recommend the combination for randomised trials, with response rate 95% confidence limits of between 8% and 30%, and a power of 91%.
The significance of the difference between the proportions of patients experiencing pain and responding versus not responding was measured using the Fisher's exact test. Blood pressure and heart rate data were analysed using nonparametric (Kruskal-Wallis and Wilcoxon signed rank) and parametric tests (analysis of variance and paired t-test) to calculate the statistical significance of differences between multiple groups and two groups, respectively. P < 0.05 was considered significant.
results patient demographics and characteristics
Five of the first 18 patients (28%) had disease that responded (one by RECIST, two by CA 125, two by both RECIST and CA 125), so the study was extended and closed after 44 patients were recruited between December 2005 and December 2008.
Patient characteristics are listed in Table 1 . There were two patients where it was not clear whether the primary tumour was ovarian or peritoneal. Almost all patients had platinum-based chemotherapy as the last therapy before study entry. Three patients had received non-platinum therapy within the 6-month platinum-free interval. Seventy-seven percent had received at least one prior taxane-containing regimen. The median platinum-free interval was 20 weeks, with three patients starting trial treatment between 26 and 32 weeks after their last platinum therapy (but they all had progressed within 6 months) and before an amendment clarifying our definition of platinum resistance (see 'Patients and Methods' section).
treatment
A total of 183 cycles were given to 44 patients, with 20 patients (46%) completing all six cycles (Table 2) . Fifteen patients (34%) Annals of Oncology original article withdrew due to tumour progression; seven patients (16%) came off trial due to adverse events (AEs) that are mostly attributable to tumour progression as well (bowel obstruction, hydronephrosis, thrombus, fatigue, abnormal ECG, carboplatin sensitivity, vaginal bleeding); one patient (2%) withdrew consent and one patient (2%) terminated the study for other reasons.
safety
All 44 patients enrolled were assessable for toxicity. Haematologic toxic effects are summarised in Table 3 . Almost all patients experienced anaemia; most of them grade 1 or 2. Three quarters of all patients experienced grade 3/4 neutropenia, based on weekly blood counts. One patient experienced neutropenic sepsis that was associated with diarrhoea. Grade 3 or 4 thrombocytopenia was seen in 9% of patients.
The number of chemotherapy courses delayed due to haematologic toxicity is shown in Table 4 . Twenty-four patients (65%) did not have any delays. Eleven percent of all subsequent courses had to be delayed in the 37 patients receiving more than one course.
Non-haematologic drug-related toxic effects are summarised in Table 3 . These included the ones usually expected with carboplatin-paclitaxel combination therapy, and lymphocytopenia, which has already been observed in the phase I single-agent trial of CA4P [13] .
Pain was the most common AE, experienced by >91% of all patients. The most severe pain was almost invariably an exacerbation of preexisting (tumour) pain. Tumour pain typically started within 1 h of the commencement of the CA4P infusion, lasting up to a few hours. Of note, the pain often recurred with less intensity in subsequent courses. No patient stopped treatment because of pain, as it was controllable with analgesia that included morphine in 10 (23%) patients.
Cardiac side-effects initially were expected, based on earlier clinical data [21] . Hypertension occurred in 23% of patients. Both systolic and diastolic blood pressure significantly increased after 1 h versus baseline (median increase +16% and +14%, respectively) and resolved to baseline at 3 h. Four patients (9%) were given GTN sublingually because their systolic blood pressure rose above 180 mmHg. Seven patients (16%) were given prophylactic treatment with amlodipine either because they were hypertensive before treatment or because they had experienced hypertension with previous courses. Blood pressure data taken before each treatment cycle did not show a significant cumulative increase in measurements over the 18 weeks of treatment period (data not shown). Sinus tachycardia was a typical side-effect of CA4P, occurring in a total of 15 patients (34%). Heart rate significantly decreased after 1 h versus baseline (median decrease 212%), returned to normal after 2 h, and was significantly increased after 3 h, with a plateau until 6 h (median increase +12%). Other cardiac toxic effects were rare: cardiac arrhythmia, hypotension, or prolonged QTc interval was observed in two patients (5%); grade 1/2 sinus bradycardia and cardiac ischaemia occurred in one patient (2%). Parametric and nonparametric statistical tests yielded similar results for significance.
Allergic and cutaneous reactions mostly consisted of flushing, itching, rash (either at the injection site or generalised), and pyrexia. In 23 (52%) patients, these were related to CA4P, most of them (19 patients, 43%) grade 1, and Upper respiratory symptoms were related to CA4P in 10 (23%) patients and consistent mainly in grade 1 cough and pain; 2 (5%) patients experienced grade 3 chest pain, which was not of cardiac origin in nature.
Neurotoxicity presented, on the one hand, as symptoms typically associated with paclitaxel-carboplatin chemotherapy. On the other hand, short-lived sensory neuropathy lasting for minutes to hours was seen in the form of numbness (of the extremities, mouth, toes, or feet) in 5 patients; prickling or tingling of the lips, fingers, toes, buttocks, or perianal region in 10 patients; and cramps in the hand in 1 patient. Dizziness was observed in seven patients. All but two neurological AEs were graded 1 or 2. Grade 2 ataxia was seen in one patient and was deemed definitely related to CA4P. Two patients experienced grade 3 neurotoxicity: a 56-year-old patient with metastatic primary peritoneal carcinoma developed confusion after paclitaxel infusion. Magnetic resonance imaging showed a probable recent left frontal infarct but also at least eight tiny areas of older infarcts indicating preexisting vascular damage. The patient recovered clinically completely from the event. The event was deemed possibly drug related, but it was noted that the patient already had episodes of memory loss over 2 weeks before treatment. The second patient, a 44-year-old patient with ovarian carcinoma, developed grade 3 sensory neurotoxicity after CA4P, which resolved completely within 48 h. Upper respiratory symptoms in 14 patients (32%) consisted of dyspnoea, cough, and chest tightness. efficacy Table 5 shows RECIST and CA 125 response outcomes. Five of 37 patients assessable by RECIST (13.5%) had a confirmed partial response, 13 of 38 assessable by the GCIG CA 125 criteria responded (34%), and none of the 7 patients not assessable by RECIST responded by CA 125. The overall intention-to-treat response rate by either criteria was 29% (13 of 44), with 95% confidence intervals between 18% and 44%. A further two patients (5%) had a partial response according to RECIST, but they were not confirmed either by repeat scan or by CA 125 measurement. One patient was not assessable for response because of a lack of follow-up data due to rapid disease progression and early death.
The characteristics of the patients whose disease responded are shown in Table 6 . All such patients received carboplatin as single, or as part of combination, chemotherapy within <6 months before the first day of study treatment, except for one patient who exceeded this interval by 4 days. Three of five patients with RECIST and GCIG CA 125 responses had received prior taxane chemotherapy. In addition, CA 19-9, carcinoembryonic antigen, and CA 125 levels all decreased in a patient with mucinous ovarian cancer and nonevaluable pulmonary lymphangitis and her PS was 
Weekly full blood counts were performed. There is considerable current interest in agents that can improve response to chemotherapy in patients with platinumresistant ovarian cancer, a patient population with a particularly dismal prognosis [22] . This single-arm phase II study was carried out to evaluate the feasibility of combining CA4P with carboplatin and paclitaxel and its activity in patients with platinum-resistant ovarian cancer, based on a phase Ib trial with escalating doses of this drug combination that showed responses especially in ovarian cancer patients [17] . This study shows that the combination of CA4P 63 mg/m 2 , carboplatin AUC 5, and paclitaxel 175 mg/m 2 is well tolerated and that 29% of patients responded according to RECIST and/or GCIG CA 125 criteria.
The fact that there is no cumulative haematotoxicity when CA4P is given 18-h before paclitaxel and carboplatin contrasts with a previous phase I study, when CA4P was given 1 h after carboplatin, resulting in 56% grade 3/4 dose-limiting thrombocytopenia due to a pharmacokinetic interaction between CA4P and carboplatin clearance [16] . The proportion of 9% grade 3/4 thrombocytopenia resembles that seen in the phase I part of the study and, with regard to thrombocytopenia and neutropenia, is in the range of toxic effects observed with comparable regimens of paclitaxelcarboplatin chemotherapy [23] . Lymphopenia is a side-effect that was already observed in phase I trials of CA4P, although less pronounced.
The clinical significance of pain, usually occurring within 1 h of the commencement of the CA4P infusion in some patients, remains unclear. Although patients whose disease responded were more likely to experience pain (67%) compared with those whose disease did not respond (48%), this correlation was not statistically significant. It was important that both treating physicians and patients were aware that pain might occur after infusion of CA4P, and counteractive measures could be taken quickly, including the administration of morphine in 23% of patients. Of note, no patient had to stop treatment because of pain.
Cardiac toxicity has been acceptable with hypertension of short duration and easily controlled by GTN or premedication with amlodipine. GTN was given sublingually initially, but we now give GTN by dermal patch as it is better tolerated. QTc interval prolongations were observed in fewer patients than anticipated from earlier data [21] .
It is important to compare the 29% response rate seen in this trial with the response rates seen with other agents. Much confusion has occurred as some publications call patients' disease platinum resistant if it recurs within 6 months, but can be treated later, while others insist that patients have a treatment-free interval from last platinum of <6 months. Furthermore, some authors accept an asymptomatic rise in CA 125 alone, while others require symptoms in addition and others insist on RECIST-defined disease to indicate relapse [18] . In our study, patients were required to start trial therapy within 6 months of their last chemotherapy and if for rising CA 125, they also had to be symptomatic. It is surprising that the RECIST response rate is so much lower than the CA 125 response rate; but reassuringly, CA 125 responses were only seen in those who had a response (confirmed or unconfirmed) or stable disease by RECIST. Only a randomised trial with progression-free survival as well as response rate as end points will determine whether the higher response rate seen by CA 125 than by RECIST is a true or false representation of antitumour activity. original article
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Lessons learnt from gemcitabine, trabectedin, and canfosfamide show that the results of phase III trials may be more sobering than those of earlier phase trials [24] [25] [26] .
We used the standard 3-weekly regimen of carboplatin and paclitaxel. Recent reports suggest that dose-dense therapy produces a higher response rate [27, 28] , but so far only one study has shown that this translates into improved survival [29] .
A response rate of 29% in platinum-resistant ovary and primary peritoneal cancers is encouraging, especially if one considers an additional two (5%) patients with unconfirmed responses on computed tomography scans. Although our definition of platinum resistance meant we were treating patients with a worse prognosis than in many platinumresistant studies, only a randomised, controlled trial can confirm that the addition of CA4P to paclitaxel and carboplatin does produce a benefit. 
